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products of L-arginine, decrease nitric oxide (NO) availability. Their elevated levels in diabetes increase the risk of
acute myocardial infarction (MI), through endothelial dysfunction.
Aims: We investigated the relationship between circulating levels of ADMA, SDMA and functional relevant
parameters in patients with acute MI.
Methods: Prospective study from 31 MI patients hospitalized b12 h after symptom onset. Blood samples were
taken on admission and serum levels of ADMA, SDMA and L-arginine were determined using high-
performance liquid chromatography (HPLC).
Results:Mean age was 65y, most were male, hypertensive, 1/3rd were current smokers, or had a history of CAD
and 23% were diabetic. ADMA and L-arginine values were similar whatever the risk factor, except for ADMA that
was positively correlated with blood glucose (r = 0.37). In contrast, SDMA was correlated with age (r = 0.43),
and admission glucose (r = 0.57). SDMA was elevated in hypertension, prior CAD, statin therapy and showed
a trend toward an increase in diabetic patients (p = 0.191). Moreover, there was a trend toward an elevation
of SDMA with decreased LVEF (r =−0.25). In multivariate linear regression analysis, blood glucose was an es-
timate of SDMA (ß= 0.373, p = 0.025), beyond traditional markers of dimethylarginines including kidney fail-
ure.
Conclusion: Our study showed that in patients with acuteMI, SDMA, and only weakly ADMA, are associatedwith
admission blood glucose, beyond traditional dimethylarginine determinants and may therefore have biological
activity beyond renal function.





Acute myocardial infarction1. Introduction
L-Arginine (L-arg) is the precursor for the synthesis of nitric oxide
(NO), a key signalingmolecule via NO synthase (NOS). ReducedNObio-
availability may play an essential role in cardiovascular pathologies and
metabolic diseases. L-arg deﬁciency syndromes in humans involveting enzyme inhibitor; ARB,
ethylarginine; BMI, body mass
RP, C-reactive protein; DBP, di-
l; HbA1c, glycated hemoglobin;
erformance liquid chromatog-
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levation myocardial infarction.
eller).
pen access article under the CC BY-Nendothelial inﬂammation and immune dysfunctions [1]. The synthesis
of NO is selectively inhibited by guanidino-substituted analogs of L-arg
or methylarginines such as asymmetric dimethylarginine (ADMA),
which results from protein degradation in cells. Many disease states,
including cardiovascular diseases and diabetes, are associated with in-
creased plasma levels of ADMA. Methylated arginines: ADMA and
symmetric (SDMA) dimethyl-L-arginine are produced by the meth-
ylation of protein arginine residues, in the reaction catalyzed by
arginine methyltransferases (PRMT). Most ADMA, but not SDMA,
is degraded to citrulline and dimethylamine by dimethylarginine
dimethylaminohydrolase (DDAH) wich is widely distributed
throughout the organs and tissues, particularly in the liver and kid-
ney. DDAH presents two isoforms: I and II; this way regulates
ADMA levels and hence NO synthesis [2].
Unlike ADMA, which is a primary factor in the control of NOS activ-
ity, SDMA has insigniﬁcant inhibitory effects on the enzyme but mightC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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tion into the cell. SDMA is highly related to renal function [3], as urinary
excretion is considered as the main route for elimination of SDMA, al-
though it has been demonstrated in humans that the liver contributes
in the elimination of SDMA [4].
Moreover, several lines of evidence have demonstrated that ele-
vated ADMA levels are associated with endothelial cell (EC) dys-
function in healthy subjects and in patients with metabolic disease
[5]. A positive relationship between long-term glycaemic control
and plasma ADMA levels has been reported in patients with diabe-
tes mellitus (DM), associated with micro- and macrovascular com-
plications [6]. Moreover, a negative relationship has been reported
between SDMA and insulin resistance [7]. SDMA, which is not a
competitive inhibitor of NO synthase, failed to show any indepen-
dent relationship with LDL-cholesterol. The signiﬁcant link be-
tween ADMA and HDL-C level may be due to the modulation of
eNOS activity [8]. Several studies reported that hyperglycemia in-
duces modiﬁcations in HDLs, and LDLs functions, and is associated
with inﬂammation and demonstrated that targeting inﬂammation
improves glycemia, insulin resistance, and inﬂammatory proﬁles in
patients at risk for development of cardiovascular and metabolic pa-
thologies. It is well known that the intact endothelium may actively
contribute to atherosclerotic disease initiation and/or progression.
The underlying mechanisms leading to dysfunctional EC are not
clear. Moreover, EC are heterogeneous in their response to physio-
pathological stimuli [9].
In patients with coronary artery disease (CAD), including acute
myocardial infarction (MI), there is little information on the
relationship between L-arg metabolism, NO bioavailability, glyce-
mia and inﬂammation. Therefore, we aimed to examine the relation
between plasma dimethylarginines, blood glucose, and a traditional
marker of inﬂammation such as C-reactive protein (CRP) levels in
patients hospitalized for acute MI.2. Methods
2.1. Patients
The participants were recruited from the Observatoire des
Infarctus de Côte d'Or (RICO) survey, a French regional survey of
acute MI. Details on the survey have already been published [10].
In the present study, patients admitted to an intensive care unit
between 4th May 2012 and 23rd January 2014 for acute MI within
12 h after symptom onset were included. MI was deﬁned by an
increase in serum troponin Ic [Nupper limit of the hospital normal
(ULN) range] associated with symptoms of ischemia and/or typical
ECG signs [11]. ST-segment elevation MI (STEMI) was deﬁned as
chest pain lasting for ≥20 min with typical ECG changes including
≥1 mV ST segment elevation in two or more limb leads or ≥2 mV
in two or more contiguous precordial leads. We collected data on
patients' age, sex, cardiovascular risk factors (history of hyperten-
sion or treated hypertension, known history of diabetes, treated
hypercholesterolaemia, body mass index (kg/m2), current smoking
(within three months)) and chronic treatments. Hemodynamic
parameters on admission (heart rate, systolic and diastolic blood
pressures), and Killip class N1 were also gathered. Left ventricular
ejection fraction (LVEF) was measured by echocardiography 2 ±
1 day after admission using the Simpson method.
Blood samples for the assessment of biomarkers levels were
collected on admission in EDTA containing tubes and stored at
−80 °C until analysis.
The study was approved by the Consultative Committee of
Protection of Persons in Biomedical Research of Burgundy and
conducted in accordance with Declaration of Helsinki. All subjects
gave their written consent to participate in the study.2.2. Biological data
Blood samples were drawn on admission (Median time from symp-
tom onset to blood sampling: 16 (8–30) hours). C-reactive protein
(CRP), total cholesterol (TC), high-density lipoprotein cholesterol
(HDL-C) and triglyceride (TG) concentrations were measured on a
Dimension analyzer (Dade Behring, Newark, NE). The level of low-
density lipoprotein cholesterol (LDL-C) was calculated using the
Friedewald formula [12]. Plasma glucose concentrations (enzymatic
method (glucose oxidase)) and creatinine levels were measured on a
Vitros 950 analyzer (Ortho Clinical Diagnostics, Rochester, NY) and cre-
atinine clearance was calculated with the Cockcroft formula. Glycated
hemoglobin A1c (HbA1c) was measured with ion exchange HPLC
(Bio-Rad Laboratories, Richmond, CA).
2.3. Dimethylarginines and L-arginine analysis
Samples were allowed to clot at room temperature for 30 min and
centrifuged at 2500 rpm for 10 min at 4 °C. The serum was kept frozen
at−80 °C until analysis. L-arginine, ADMA, and SDMA, were measured
by high performance liquid chromatography (HPLC) [13]. Before the
analysis, serum was added with N-monomethyl L-arginine (NMMA) as
the internal standard and phosphate–buffered saline (PBS). This mixture
was extracted on solid-phase extraction (SPE) cartridges (Phenomenex
Strata X-C, Torrance, CA, USA). The cartridges were ﬁrst conditioned
with elution buffer (10/0.5/40/50; NH3 concentrated/1 M NaOH/
bidistilled water/CH3OH; v/v/v/v) followed by bidistilled water before
being loadedwith the diluted sample. The SPE cartridgewas consecutive-
ly washed with HCl (100 mmol/L) and methanol (1:1; v:v). ADMA and
SDMAwere elutedwith elution buffer. All conditioning,washing and elu-
tion steps were achieved by vacuum suction. The eluate was dried under
nitrogen, derivatized with ortho-phthaldialdehyde (OPA) reagent (1:1;
v:v) and injected into the HPLC system, with a ﬂuorescent detector
Finingan Surveyor (Thermo Fisher (lexc: 340 nm, lem: 455 nm) and
ChromolithH RP-18E column (10,064.6 mm) including a guard cartridge
(1064.6 mm) supplied by Merck (Darmstadt, Germany). Chromato-
graphic separation, at room temperature, was performed isocratically at
100%mobile phaseA,with 25mmol/L phosphate buffer (pH6.8) contain-
ing 6.5% CH3CN, at a ﬂow rate of 1.1mL/min. After SDMA elution, mobile
phase was switched to 100% mobile phase B, with ultrapure water:
CH3CN (50:50, v:v), and the ﬂow rate was increased to 3.0 mL/min to
elute strongly retained compounds. Assays were performed in duplicate.
The detection limitswere 0.05 and 1.19mmol/L and interday variabilities
were 5.7 and 4.6% for ADMA and L-arginine, respectively [14].
2.4. Statistical analysis
Dichotomous variables are expressed as n (%) and continuous vari-
ables as mean ± SD or median (interquartile range). A Kolmogorov–
Smirnov test was performed to assess the normality of continuous
variables. Mann–Whitney test or Student's t test was used to compare
continuous data, and the Chi 2 test or Fisher's test was used for dichot-
omous data. The threshold for signiﬁcancewas set at 5%. For continuous
variables, Pearson or Spearman rank correlation analyses were per-
formed, as appropriate. Multiple linear regression analysis was per-
formed with SDMA as a dependent variable. Variables entered into the
models were those with a signiﬁcant relationship (p b 0.05) with the
dependent variable in univariate analysis (i.e. hypertension, family
history of CAD, age, creatinine clearance, and admission blood glucose).
The threshold for signiﬁcance was set at 5%. SPSS version 12.0.1 (IBM
Inc., USA) was used for all of the statistical tests.
3. Results
Mean agewas 65 years, most weremale and hypertensive, almost
1/3rd were current smokers, or had a history of CAD (Table 1).
Table 1
Dimethylarginines and L-arginine according to baseline characteristics.
N(%) or Mean ± SD ADMA, μmol/L or r p SDMA μmol/L or r p L-arginine μmol/L or r p
All 31 0.52 ± 0.11 0.69 ± 0.35 93.30 ± 44.81
Risk factors
Age, y 65 ± 16 0.200 0.281 0.435 0.015 0.214 0.248
Female Yes 12(39%) 0.51 ± 0.13 0.846 0.70 ± 0.41 0.912 90.62 ± 44.81 0.796
No 19(61%) 0.52 ± 0.10 0.68 ± 0.33 94.99 ± 45.96
BMI, kg/m2 27 ± 5 0.071 0.706 0.003 0.989 0.193 0.299
Hypertension Yes 18(58%) 0.52 ± 12 0.598 0.80 ± 0.41 0.022 98.5253.86 0.455
No 13(42%) 0.50 ± 0.11 0.54 ± 0.17 86.07 ± 28.52
Diabetes Yes 7(23%) 0.53 ± 0.16 0.651 0.84 ± 0.48 0.191 71.72 ± 23.31 0.151
No 24(67%) 0.51 ± 0.10 0.64 ± 0.30 99.59 ± 47.90
Hypercholesterolemia Yes 14(45%) 0.49 ± 0.13 0.344 0.82 ± 0.47 0.092 96.14 ± 62.99 0.774
No 17(55%) 0.53 ± 0.09 0.58 ± 0.17 90.96 ± 23.01
Current smoking Yes 10(32%) 0.51 ± 0.10 0.913 0.55 ± 0.21 0.127 104.61 ± 38.65 0.341
No 21(68%) 0.52 ± 0.12 0.76 ± 0.39 87.9 ± 47.39
Family history of CAD Yes 14(45%) 0.49 ± 0.08 0.349 0.66 ± 0.24 0.638 84.25 ± 23.91 0.316
No 17(55%) 0.53 ± 0.13 0.72 ± 0.43 100.75 ± 56.31
CV history
History of CAD Yes 10(32%) 0.53 ± 0.14 0.631 0.95 ± 0.50 0.036 77.03 ± 26.86 0.167
No 21(68%) 0.51 ± 0.10 0.56 ± 0.16 101.05 ± 49.92
Chronic kidney disease Yes 2(6%) 0.41 ± 0.11 0.108 0.96 ± 0.23 0.091 115.91 ± 7.37 0.077
No 29(94%) 0.52 ± 0.11 0.67 ± 0.36 91.74 ± 45.94
Admission data
Anterior wall location Yes 10(32%) 0.49 ± 0.11 0.463 0.66 ± 0.21 0.767 98.77 ± 60.6 0.647
No 21(68%) 0.53 ± 0.11 0.70 ± 0.41 90.69 ± 36.75
STEMI Yes 12(39%) 0.49 ± 0.11 0.321 0.54 ± 0.17 0.029 109.42 ± 65.79 0.203
No 19(61%) 0.53 ± 0.11 0.78 ± 0.41 83.12 ± 20.56
HF on admission Yes 8(26%) 0.55 ± 0.18 0.486 1.05 ± 0.53 0.037 112.02 ± 65.12 0.174
No 23(74%) 0.50 ± 0.08 0.56 ± 0.14 86.79 ± 34.90
HR, b/min 79 ± 15 −0.046 0.815 −0.139 0.480 0.001 0.996
SBP, mmHg 134 ± 28 −0.060 0.752 −0.150 0.430 −0.158 0.406
DBP, mmHg 78 ± 18 −0.158 0.404 −0.208 0.271 0.033 0.861
LVEF, % 50 ± 13 0.050 0.788 - 0.246 0.182 0.098 0.601
GRACE risk score 147 ± 44 0.311 0.108 0.563 0.002 0.011 0.957
Biological data
ADMA, μmol/L - - 0.535 0.002 −0.104 0.577
SDMA, μmol/L 0.535 0.002 - - −0.072 0.700
L-arginine, μmol/L −0.104 0.577 −0.072 0.700 - -
Creatinine Cl, mL/min 74 ± 27 0.330 0.070 −0.773 b0.001 0.181 0.331
Total-cholest, mg/dL 1.87 ± 0.41 −0.024 0.901 −0.440 0.015 0.170 0.370
LDL-cholest, mg/dL 1.18 ± 0.41 −0.106 0.583 −0.548 0.002 0.232 0.226
HDL-cholest, mg/dL 0.43 ± 0.12 0.039 0.840 0.148 0.435 −0.144 0.449
Triglycerides, mg/dL 1.04(0.77–1.47) 0.102 0.590 0.095 0.616 0.043 0.822
Glucose, mmol/L 7.9 ± 3.4 0.372 0.040 0.575 0.001 −0.248 0.178
HbA1C, % 6.0(5.7–6.4) −0.187 0.323 0.095 0.616 −0.077 0.685
CRP, mg/L 5.4(2.8–24.8) −0.105 0.581 0.035 0.854 0.261 0.164
CRP N3 yes 18(58%) 0.52 ± 0.13 0.391 0.73 ± 0.44 0.260 101.63 ± 52.62 0.197
no 12(42%) 0.49 ± 0.06 0.60 ± 0.14 79.52 ± 29.26
NT-proBNP, pg/mL 1037(456–3062) 0.074 0.692 0.390 0.030 −0.191 0.304
Troponin Ic, μg/L 40(7–86) −0.293 0.116 0.234 0.213 −0.038 0.840
CK, IU/L 1268 ± 1311 −0.120 0.520 0.017 0.926 −0.091 0.625
Hemoglobin, g/dL 14.1 ± 1.8 −0.070 0.708 −0.273 0.138 −0.336 0.064
Hematocrit, % 42 ± 5 −0.040 0.841 −0.170 0.360 −0.347 0.056
Chronic treatments
Diuretic yes 9(29%) 0.52 ± 0.16 0.795 0.96 ± 0.53 0.063 97.41 ± 65.79 0.750
no 22(71%) 0.51 ± 0.09 0.58 ± 0.17 91.62 ± 34.78
ACE inhibitor yes 6(19%) 0.57 ± 0.16 0.222 1.07 ± 0.55 0.090 111.44 ± 75.58 0.277
no 25(81%) 0.50 ± 0.10 060 ± 0.22 88.94 ± 34.91
Oral antidiabetic yes 6(19%) 0.48 ± 0.08 0.348 0.69 ± 0.26 0.981 70.49 ± 25.28 0.169
no 25(81%) 0.52 ± 0.12 0.69 ± 0.38 98.77 ± 47.07
Insulin yes 5(16%) 0.59 ± 0.16 0.116 0.94 ± 0.55 0.086 75.63 ± 27.20 0.344
no 26(84%) 0.50 ± 0.10 0.64 ± 0.30 96.70 ± 47.09
Statin yes 9(29%) 0.50 ± 0.16 0.731 0.98 ± 0.51 95.74 ± 66.44 0.850
no 22(71%) 0.52 ± 0.09 0.57 ± 0.17 0.046 92.30 ± 34.41
Acute treatments
Diuretic yes 5(16%) 0.56 ± 0.19 0.290 1.26 ± 0.54 0.045 83.92 ± 29.62 0.618
no 26(84%) 0.51 ± 0.09 0.58 ± 0.16 95.10 ± 47.42
ACE inhibitor yes 12(39%) 0.49 ± 0.09 0.360 0.55 ± 0.14 0.034 104.04 ± 52.77 0.297
no 19(61%) 0.53 ± 0.12 0.78 ± 0.42 86.51 ± 38.99
Oral antidiabetics yes 2(6%) 0.41 ± 0.10 0.127 0.62 ± 0.25 0.936 84.25 ± 37.40 0.936
no 29(94%) 0.52 ± 0.11 0.69 ± 0.36 93.92 ± 45.78
Insulin yes 8(26%) 0.56 ± 0.17 0.372 0.87 ± 0.45 0.097 76.34 ± 25.22 0.220
no 23(74%) 0.50 ± 0.08 0.63 ± 0.30 99.20 ± 48.94
Statin yes 28(90%) 0.50 ± 0.11 0.181 0.67 ± 0.37 0.095 92.63 ± 46.94 0.256
no 3(10%) 0.62 ± 0.13 0.83 ± 0.18 99.53 ± 17.59
ADMA: Asymmetric dimethylarginine; CK: creatine kinase; CRP: C-reactive protein; HbA1c: glycated hemoglobin; HDL-C: high-density lipoprotein; LDL-C: low-density lipoprotein; SDMA:
Symmetric dimethylarginine. ACE inhibitor: angiotensin converting enzyme inhibitor; CAD: coronary artery disease; HF: heart failure; STEMI: ST segment elevation myocardial infarction;
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lin therapy and 19% under oral antidiabetic medications. Variations
of dimethylarginines and L-arginine values according to the baseline
characteristics and CV treatments are shown in Table 1. RegressionFig. 1. Regression analysis for dimethylarginines and biological variables. A: ADMAanalysis for dimethylarginines and biological variables are indicated in
Fig. 1. ADMA and L-arginine values were similar whatever the presence
or not of a risk factor or treatment, except for ADMA that was positively
correlated with blood glucose (r = 0.37)./SDMA; B: Age/SDMA; C: glucose/ADMA; D: glucose/SDMA; E: LVEF/SDMA.
10 A. Gudjoncik et al. / Clinical Trials and Regulatory Science in Cardiology 16 (2016) 6–11In contrast, SDMA was positively correlated with ADMA (r = 0.53;
Fig. 1 A); age (r = 0.43, Fig. 1 B), Nt-proBNP (r = 0.39), and even
more strongly with glucose (r = 0.57; Fig. 1 D). However, SDMA was
not related to chronic glucose control (i.e. HbA1c) (p = 0.616). SDMA
was negatively correlated with creatinine clearance (r =−0.77) and
was N50% increased with kidney failure (i.e. creatinine clearance
b60 ml/min) (0.77(0.58–1.12) vs. 0.50(0.43–0.65) μmol/L, p = 0.006).
SDMAwas signiﬁcantly elevated in hypertension, prior CAD, and chron-
ic statin therapy and showed a trend toward an increase in diabetic
patients (p = 0.191). Moreover, there was a trend toward an elevation
of SDMA with decreasing LVEF (r =−0.25; Fig. 1E) and patients with
severe LVEF alteration (b40%) showed a trend toward higher SDMA
values, but this relation was not signiﬁcant (0.86 ± 0.24 vs. 0.66 ±
0.37 μmol/L, p = 0.236).
In multivariate linear regression analysis, blood glucose level on ad-
mission was an estimate of SDMA level (ß= 0.373, p= 0.025), beyond
traditional marker of the dimethylarginine including kidney failure
(ß = 0.475, p = 0.017) and hypertension (ß = 0.379, p = 0.019).
4. Discussion
The role of ADMA as an endogenous competitive inhibitor of eNOS is
now well established, while in return SDMA is not a competitive inhib-
itor of eNOS. SDMA is a structural isomer of ADMA and inhibits cationic
amino acid transporters which are essential for the transcellular mem-
brane passage of L-arginine [2,15]. High plasma ADMA concentrations
are associated with EC dysfunction in patients with CV risk factors or
CAD,while this association isweak in healthy individuals [16]. Endothe-
lial dysfunction is primarily characterized by impaired NO-induced
vasodilation, and associated with traditional CV risk factors such as
dyslipidemia, hypertension and metabolic syndrome. More precisely,
in the vascular endothelium of CAD patients, high serum ADMA levels
are associated with impaired vascular function reﬂected by increased
vascular superoxide production and reduced NO bioavailability, due to
accelerated eNOS uncoupling [17]. In MI patients, circulating ADMA
has been independently associated with clinical outcomes probably
through its deleterious impact on vascular homeostasis. In a large pop-
ulation we showed a strong inverse relationship between HDL and
ADMA inmyocardial infarction patients, suggesting a functional interac-
tion between HDL and endothelium, beyondmetabolic conditions asso-
ciated with low HDL levels [8].
In our study, SDMA was positively related to ADMA but not with L-
arginine. These results are in agreement with previous ﬁnding from
our laboratory [18] and by another group [19]. Elevated plasma
concentrations of SDMA might also indirectly inﬂuence the activity
of NOS by inhibiting the uptake of cellular L-arginine. Hence, during
acute MI, the biochemical pathways that regulate the biological
functions of dimethylarginines appear interdependent.
Our study, as other studies [20], showed that SDMA was negatively
correlated with creatinine clearance. Circulating levels of ADMA and
SDMA are positively associated with all-cause and cardiovascular mor-
tality in patients with end-stage renal disease. Chronic kidney diseases
are associated with reduced bioavailability of NO, which is required to
maintain normal vascular and kidney function. Data from human stud-
ies have suggested that SDMA correlates well with parameters of renal
function [3]. Plasma SDMA levels increase in parallel with creatinine
and blood urea nitrogen after total nephrectomy [21]. Recently, the pos-
itive association between SDMA and increased risk is controversial [22]
according to that elevated SDMA could therefore inﬂuence the NO-
production also by inhibiting the transportation of arginine.
The main ﬁndings in this study are that ADMA was positively
correlated with admission blood glucose. A variety of studies have
demonstrated that elevated ADMA contributed to endothelial dys-
function, the common characteristic of diabetes [23,24]. It has
been well documented that diabetes impairs endothelial cells and
attenuates endothelial repair and angiogenesis, which are closelyassociated with the increased prevalence of cardiovascular diseases.
The exact mechanisms underlying the disease are unknown; however,
there is growing evidence that excess generation of reactive oxygen spe-
cies (ROS), largely due to hyperglycemia, causes oxidative stress in a va-
riety of tissues. One of the mechanisms relates to the fact that the
reaction of NO with superoxide anion results in its inactivation and
therefore induces a reduction in the biological availability of NO
[25]. What are themechanisms implicated in the positive correlation
between ADMA and blood glucose? One of the mechanisms is the in-
cidence of glucose on the activity of enzymes involved in ADMAme-
tabolism. ADMA is metabolized to L-citrulline and dimethylamine by
dimethylarginine dimethylaminohydrolase (DDAH). DDAH has two
isoforms, DDAH1 and DDAH2. It has been reported that high glucose
level decreased the activity and expression of DDAH2, one of the
major isoforms of DDAH in endothelial cell, indicating that DDAH2/
ADMA pathway play important role in endothelial cell senescence
in diabetes [26].
Interestingly, we observed that ADMA was not positively correlated
with CRP in acute MI. CRP is an acute phase reactant in acute MI, and
many studies have demonstrated the prognostic signiﬁcance ofmarkers
of inﬂammation such as CRP, and oxidative stress [27]. There have been
extensive investigations about the role of CRP in CAD over the past few
years and it has been reported thatmeasurement of CRP levelsmight be
a useful assessment in patients at intermediate risk for cardiovascular
events. CRP directly inhibits NO production by EC via destabilizing
eNOS. The eNOS activity and eNOS dimer/monomer ratio were sig-
niﬁcantly lower in aortic tissue homogenates from CRP-treated rats
associated with signiﬁcant reductions in guanosine triphosphate
cyclohydrolase 1 (GTPCH1) expression and tetrahydrobiopterin
(BH4) levels. GTPCH 1 and BH4 are involved in endothelial nitric
oxide production and, their depletion may lead to decreased avail-
ability of NO [2,28]. The underlying mechanisms of this lack of corre-
lation remain unclear. One emerging hypothesis, based on
experimental ﬁndings, suggests an effect of inﬂammation process
on enzymes activities associated with ADMAmetabolism. Moreover,
SDMA, which is not a competitive inhibitor of NO synthase, failed to
show any relationship with CRP levels. ADMA has been implicated in
inﬂammation response through activation of leukocyte adhesion
and production of inﬂammatory cytokine tumor necrosis factor α
(TNF-α) in cultured endothelial cells or monocytes [29]. Accumula-
tion of ADMA is a result of increased production and/or reduced deg-
radation. It has been reported that mRNA and protein expression of
DDAH2 not DDAH1 were markedly decreased in synoviocytes of
collagen-induced arthritis rats. There is growing evidence that
1) the expression of DDAH2, the key enzyme for ADMA degradation,
was markedly reduced in inﬂamed tissue 2) ADMA is not only a risk
factor for endothelial dysfunction but also a novel proinﬂammatory
mediator [30].5. Limitations of the study
Our study is limited by its design. This work suffers from the usual
limitations of observational, and therefore determines correlations rather
than causal relationship. The number of patients included was relatively
small (n = 31). The small number of subjects also limits interpretation
of correlation between functional parameters and biological values.Funding
This work was supported by INSERM, the University Hospital of
Dijon and Association de Cardiologie de Bourgogne, and by grants
from the Conseil Régional de Bourgogne, Fédération Française de
Cardiologie (FFC), Société Française de Cardiologie (SFC) and Agence
Régionale de Santé de Bourgogne.
11A. Gudjoncik et al. / Clinical Trials and Regulatory Science in Cardiology 16 (2016) 6–11Conﬂict of interest
The authors have no potential conﬂicts of interest to disclose in
connection with the submitted article.
Acknowledgments
We wish to thank Maud Maza, Aline Chagnon and Florence Bichat
for their research assistance, Edith Fusier for her editorial support and
Philip Bastable for his English assistance.
References
[1] Lorin J, Zeller M, Guilland J-C, Cottin Y, Vergely C, Rochette L. Arginine and nitric
oxide synthase: regulatory mechanisms and cardiovascular aspects. Mol Nutr Food
Res 2014;58:101–16.
[2] Rochette L, Lorin J, ZellerM, Guilland JC, Lorgis L, Cottin Y, Vergely C. Nitric oxide syn-
thase inhibition and oxidative stress in cardiovascular diseases: possible therapeutic
targets? Pharmacol Ther 2013;140:239–57.
[3] Kielstein JT, Salpeter SR, Bode-Boeger SM, Cooke JP, Fliser D. Sym`metric
dimethylarginine (SDMA) as endogenous marker of renal function—a meta-
analysis. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc – Eur Ren
Assoc 2006;21:2446–51.
[4] Siroen MPC, van der Sijp JRM, Teerlink T, van Schaik C, Nijveldt RJ, van Leeuwen
PAM. The human liver clears both asymmetric and symmetric dimethylarginine.
Hepatol Baltim Md 2005;41:559–65.
[5] Juonala M, Viikari JS, Alfthan G, Marniemi J, Kähönen M, Taittonen L, Laitinen T,
Raitakari OT. Brachial artery ﬂow-mediated dilation and asymmetrical
dimethylarginine in the cardiovascular risk in young Finns study. Circulation 2007;
116:1367–73.
[6] Hanai K, Babazono T, Nyumura I, Toya K, Tanaka N, Tanaka M, Ishii A, Iwamoto Y.
Asymmetric dimethylarginine is closely associated with the development and pro-
gression of nephropathy in patients with type 2 diabetes. Nephrol Dial Transplant
Off Publ Eur Dial Transpl Assoc Eur Ren Assoc 2009;24:1884–8.
[7] Zsuga J, Török J, Magyar MT, Valikovics A, Gesztelyi R, Lenkei A, Csiba L, Kéki S, Zsuga
M, Bereczki D. Dimethylarginines at the crossroad of insulin resistance and athero-
sclerosis. Metabolism 2007;56:394–9.
[8] Lorin J, Guilland J-C, Korandji C, Touzery C, Bichat F, Chagnon A, Cottin Y, Rochette L,
Vergely C, Zeller M. High levels of asymmetric dimethylarginine are strongly associ-
ated with low HDL in patients with acute myocardial infarction. PLoS One 2013;8,
e64796.
[9] Favero G, Paganelli C, Buffoli B, Rodella LF, Rezzani R. Endothelium and its alterations
in cardiovascular diseases: life style intervention. Biomed Res Int 2014;2014:
801896.
[10] Zeller M, Steg PG, Ravisy J, Lorgis L, Laurent Y, Sicard P, Janin-Maniﬁcat L, Beer JC,
Makki H, Lagrost AC, Rochette L, Cottin Y, Survey Working Group RICO. Relation be-
tween body mass index, waist circumference, and death after acute myocardial in-
farction. Circulation 2008;118:482–90.
[11] Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redeﬁned–a con-
sensus document of the joint European society of cardiology/American college of
cardiology committee for the redeﬁnition of myocardial infarction. J Am Coll Cardiol
2000;36:959–69.
[12] Warnick GR. Laboratory measurement of lipid and lipoprotein risk factors. Scand J
Clin Lab Investig Suppl 1990;198:9–19.
[13] Ivanova M, Artusi C, Boffa GM, Zaninotto M, Plebani M. HPLC determination of
plasma dimethylarginines: method validation and preliminary clinical application.
Clin Chim Acta Int J Clin Chem 2010;411:1632–6.[14] Korandji C, ZellerM, Guilland J-C, Vergely C, Sicard P, Duvillard L, Gambert P, Moreau
D, Cottin Y, Rochette L. Asymmetric dimethylarginine (ADMA) and hyperhomocys-
teinemia in patients with acute myocardial infarction. Clin Biochem 2007;40:66–72.
[15] Cooke JP. Asymmetrical dimethylarginine: the Uber marker? Circulation 2004;109:
1813–8.
[16] Fard A, Tuck CH, Donis JA, Sciacca R, Di Tullio MR, Wu HD, Bryant TA, Chen NT,
Torres-Tamayo M, Ramasamy R, Berglund L, Ginsberg HN, Homma S, Cannon PJ.
Acute elevations of plasma asymmetric dimethylarginine and impaired endothelial
function in response to a high-fat meal in patients with type 2 diabetes. Arterioscler
Thromb Vasc Biol 2000;20:2039–44.
[17] Antoniades C, Shirodaria C, Leeson P, Antonopoulos A, Warrick N, Van-Assche T,
Cunnington C, Tousoulis D, Pillai R, Ratnatunga C, Stefanadis C, Channon KM.
Association of plasma asymmetrical dimethylarginine (ADMA) with elevated
vascular superoxide production and endothelial nitric oxide synthase uncoupling:
implications for endothelial function in human atherosclerosis. Eur Heart J 2009;
30:1142–50.
[18] Zeller M, Korandji C, Guilland J-C, Sicard P, Vergely C, Lorgis L, Beer JC, Duvillard L,
Lagrost AC, Moreau D, Gambert P, Cottin Y, Rochette L. Impact of asymmetric
dimethylarginine on mortality after acute myocardial infarction. Arterioscler
Thromb Vasc Biol 2008;28:954–60.
[19] Henrohn D, Sandqvist A, Egeröd H, Hedeland M, Wernroth L, Bondesson U,
Wikström G. Changes in plasma levels of asymmetric dimethylarginine, symmetric
dimethylarginine, and arginine after a single dose of vardenaﬁl in patients with
pulmonary hypertension. Vasc Pharmacol 2015.
[20] Böger RH, Zoccali C. ADMA: a novel risk factor that explains excess cardiovascular
event rate in patients with end-stage renal disease. Atheroscler Suppl 2003;4:23–8.
[21] Carello KA, Whitesall SE, Lloyd MC, Billecke SS, Alecy LGD’. Asymmetrical
dimethylarginine plasma clearance persists after acute total nephrectomy in rats.
Am J Physiol Heart Circ Physiol 2006;290:H209–16.
[22] Hov GG, Aasarød KI, Sagen E, Åsberg A. Arginine, dimethylated arginine and
homoarginine in relation to cardiovascular risk in patients with moderate chronic
kidney disease. Clin Biochem 2015;48:646–51.
[23] Anderssohn M, Schwedhelm E, Lüneburg N, Vasan RS, Böger RH. Asymmetric
dimethylarginine as a mediator of vascular dysfunction and a marker of cardiovas-
cular disease and mortality: an intriguing interaction with diabetes mellitus. Diab
Vasc Dis Res 2010;7:105–18.
[24] Yuan Q, Hu C-P, Gong Z-C, Bai YP, Liu SY, Li YJ, Jiang JL. Accelerated onset of senes-
cence of endothelial progenitor cells in patients with type 2 diabetes mellitus: role
of dimethylarginine dimethylaminohydrolase 2 and asymmetric dimethylarginine.
Biochem Biophys Res Commun 2015;458:869–76.
[25] Rochette L, Zeller M, Cottin Y, Vergely C. Diabetes, oxidative stress and therapeutic
strategies. Biochim Biophys Acta 1840;2014:2709–29.
[26] Thum T, Tsikas D, Stein S, Schultheiss M, Eigenthaler M, Anker SD, Poole-Wilson PA,
Ertl G, Bauersachs J. Suppression of endothelial progenitor cells in human coronary
artery disease by the endogenous nitric oxide synthase inhibitor asymmetric
dimethylarginine. J Am Coll Cardiol 2005;46:1693–701.
[27] Lorgis L, Zeller M, Dentan G, Sicard P, Richard C, Buffet P, L'Huillier I, Beer JC, Cottin Y,
Rochette L, Vergely C. The free oxygen radicals test (FORT) to assess circulating
oxidative stress in patients with acute myocardial infarction. Atherosclerosis 2010;
213:616–21.
[28] Verhaar MC, Westerweel PE, van Zonneveld AJ, Rabelink TJ. Free radical production
by dysfunctional eNOS. Heart Br Card Soc 2004;90:494–5.
[29] Chen M-F, Xie X-M, Yang T-L, Wang YJ, Zhang XH, Luo BL, Li YJ. Role of asymmetric
dimethylarginine in inﬂammatory reactions by angiotensin II. J Vasc Res 2007;44:
391–402.
[30] Chen X-M, Xia J, Zhou T, Yuan Q, Zhang WF, Hu CP, Li YJ, Jiang JL. Involvement of
DDAH/ADMA pathway in the pathogenesis of rheumatoid arthritis in rats. Int
Immunopharmacol 2013;16:322–31.
